Current Report Filing (8-k)

Date : 12/21/2018 @ 9:59PM
Source : Edgar (US Regulatory)
Stock : Actinium Pharmaceuticals Inc (ATNM)
Quote : 0.2483  -0.0117 (-4.50%) @ 10:59PM
After Hours
Last Trade
Last $ 0.25 ▲ 0.00 (0.12%)

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 18, 2018

 

ACTINIUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-52446   74-2963609
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

275 Madison Avenue, 7th Floor
New York, NY
  10016
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (646) 677-3870

 

N/A
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

  

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 On December 18, 2018, Actinium Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 114,698,044 shares of the Company’s common stock outstanding and eligible to vote at the Annual Meeting, 90,895,072 shares, or approximately 79.3% of the eligible common stock, were present either in person or by proxy.  All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and the two director nominees were elected. The final results of the matters voted on at the Annual Meeting are provided below.

 

Proposal 1 : The following individuals were elected as Class II directors to hold office for the term described below or until his resignation, or respective successor is elected and qualified:

 

Director Name   For     Against     Abstain     Broker
Non-Votes
 
Sandesh Seth (Class II, 36 month term)     22,304,222       12,575,737       282,343       55,732,770  
Jeffrey W. Chell (Class II, 36 month term)     30,950,343       3,733,590       478,369       55,732,770  

 

Proposal 2 : Marcum LLP was ratified as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2019.

 

For:     83,450,471  
Against:     5,196,059  
Abstained:     2,248,542  

 

Proposal 3 : An amendment to the Company’s 2013 Amended and Restated Stock Plan to increase the number of shares authorized to issue under the plan by 5 million shares was approved.

 

For:       24,676,045  
Against:       10,214,692  
Abstained:       271,565  
Broker Non-Votes:       55,732,770  

 

Proposal 4 : An amendment to the Company’s charter to increase the number of shares of common stock the Company is authorized to issue to 600 million shares was approved.

 

For:       60,916,630  
Against:       28,956,647  
Abstained:       1,021,795  
Broker Non-Votes:       0  

 

1
 

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 20, 2018 ACTINIUM PHARMACEUTICALS, INC.
     
  By: /s/ Sandesh Seth
  Name: Sandesh Seth
  Title:   CEO & Chairman

 

2

 

Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Actinium Pharmaceuticals Charts.

Actinium Pharmaceuticals (AMEX:ATNM)
Intraday Stock Chart

Today : Wednesday 13 November 2019

Click Here for more Actinium Pharmaceuticals Charts.

Latest ATNM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.